Profile data is unavailable for this security.
About the company
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
- Revenue in USD (TTM)295.39m
- Net income in USD-137.25m
- Incorporated2013
- Employees375.00
- LocationDenali Therapeutics Inc161 Oyster Point BlvdSOUTH SAN FRANCISCO 94080-1910United StatesUSA
- Phone+1 (650) 866-8548
- Fax+1 (302) 655-5049
- Websitehttps://www.denalitherapeutics.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunocore Holdings PLC - ADR | 265.83m | -59.44m | 2.45bn | 497.00 | -- | 6.77 | -- | 9.21 | -1.20 | -1.20 | 5.27 | 7.23 | 0.3486 | 0.406 | 5.60 | 534,860.40 | -7.80 | -27.55 | -9.40 | -36.82 | 99.60 | -- | -22.36 | -97.12 | 5.94 | -- | 0.5489 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Iovance Biotherapeutics Inc | 1.90m | -449.64m | 2.48bn | 557.00 | -- | 3.65 | -- | 1,305.10 | -1.82 | -1.82 | 0.0077 | 2.43 | 0.0023 | -- | -- | 3,418.31 | -53.07 | -51.47 | -59.00 | -57.56 | -846.22 | -- | -23,615.70 | -137,873.80 | 4.42 | -- | 0.0015 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
| ACADIA Pharmaceuticals Inc | 813.81m | -1.71m | 2.49bn | 610.00 | -- | 5.37 | 278.94 | 3.07 | -0.0129 | -0.0129 | 4.93 | 2.81 | 1.08 | 1.85 | 10.13 | 1,363,159.00 | -0.2264 | -27.50 | -0.3579 | -32.73 | 92.27 | 95.62 | -0.2101 | -38.35 | 1.86 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
| TG Therapeutics Inc | 289.33m | 41.20m | 2.52bn | 284.00 | 73.93 | 15.74 | 60.89 | 8.71 | 0.2205 | 0.2205 | 1.97 | 1.04 | 1.01 | 0.3567 | 7.86 | 1,095,962.00 | 14.44 | -62.87 | 20.20 | -80.06 | 93.53 | -- | 14.24 | -405.03 | 2.84 | 4.01 | 0.3876 | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
| Avidity Biosciences Inc | 10.87m | -228.68m | 2.57bn | 253.00 | -- | 3.09 | -- | 236.32 | -2.95 | -2.95 | 0.1408 | 8.69 | 0.0139 | -- | -- | 42,964.43 | -29.22 | -31.61 | -31.71 | -34.45 | -- | -- | -2,103.78 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
| MoonLake Immunotherapeutics | 0.00 | -40.68m | 2.60bn | 50.00 | -- | 4.71 | -- | -- | -0.7501 | -0.7501 | 0.00 | 8.63 | 0.00 | -- | -- | 0.00 | -14.53 | -- | -15.60 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Denali Therapeutics Inc | 295.39m | -137.25m | 2.65bn | 375.00 | -- | 1.82 | -- | 8.96 | -0.9661 | -0.9661 | 2.09 | 10.21 | 0.1976 | -- | -- | 663,797.80 | -9.18 | -14.98 | -10.91 | -17.71 | -- | -- | -46.46 | -104.50 | -- | -- | 0.00 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
| Apogee Therapeutics Inc | 0.00 | -103.55m | 2.67bn | 91.00 | -- | 3.21 | -- | -- | -2.04 | -2.04 | 0.00 | 14.22 | 0.00 | -- | -- | 0.00 | -21.45 | -- | -22.20 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
| 10X Genomics Inc | 625.45m | -264.30m | 2.68bn | 1.26k | -- | 3.73 | -- | 4.29 | -2.24 | -2.24 | 5.30 | 6.01 | 0.6458 | 2.67 | 7.39 | 496,781.60 | -27.29 | -25.52 | -30.80 | -29.05 | 64.62 | 75.88 | -42.26 | -48.53 | 4.45 | -- | 0.00 | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
| Azenta Inc | 651.76m | -152.26m | 2.72bn | 3.40k | -- | 1.24 | -- | 4.18 | -2.74 | -2.71 | 11.09 | 40.70 | 0.2242 | 2.86 | 3.44 | 186,216.00 | -5.24 | -0.5934 | -5.64 | -0.6725 | 40.04 | 43.08 | -23.36 | -2.17 | 5.26 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
| Ideaya Biosciences Inc | 15.50m | -128.89m | 2.77bn | 124.00 | -- | 2.92 | -- | 178.43 | -2.00 | -2.00 | 0.2416 | 12.51 | 0.0234 | -- | 64.20 | 125,032.30 | -19.44 | -19.17 | -20.27 | -21.05 | -- | -- | -831.35 | -244.55 | -- | -- | 0.00 | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
| Janux Therapeutics Inc | 7.29m | -55.59m | 2.77bn | 64.00 | -- | 4.23 | -- | 380.68 | -1.22 | -1.22 | 0.159 | 12.65 | 0.014 | -- | 11.48 | 113,859.40 | -10.67 | -- | -10.95 | -- | -- | -- | -762.92 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
| Arcellx Inc | 131.66m | -50.54m | 2.78bn | 130.00 | -- | 5.58 | -- | 21.13 | -1.04 | -1.04 | 2.66 | 9.32 | 0.1877 | -- | -- | 1,012,792.00 | -7.21 | -38.82 | -8.96 | -45.41 | -- | -- | -38.39 | -339.38 | -- | -- | 0.0615 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
| PTC Therapeutics, Inc. | 927.56m | -579.22m | 2.79bn | 988.00 | -- | -- | -- | 3.01 | -7.69 | -7.69 | 12.28 | -11.66 | 0.5459 | 2.33 | 4.64 | 938,823.90 | -34.09 | -26.71 | -48.63 | -33.46 | 92.88 | 93.94 | -62.45 | -83.80 | 1.98 | -0.7975 | 1.72 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
| Neogen Corp | 929.24m | 1.57m | 2.85bn | 2.64k | 1,823.86 | 0.9054 | 24.17 | 3.07 | 0.0072 | 0.0072 | 4.29 | 14.52 | 0.2044 | 2.79 | 5.81 | 351,984.10 | 0.0345 | 3.44 | 0.0355 | 3.62 | 50.97 | 47.25 | 0.1685 | 7.77 | 2.66 | 1.31 | 0.2205 | 0.00 | 56.01 | 15.63 | -147.34 | -- | 25.71 | -- |
Data as of May 31 2024. Currency figures normalised to Denali Therapeutics Inc's reporting currency: US Dollar USD
50.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baillie Gifford & Co.as of 31 Mar 2024 | 14.04m | 9.85% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 10.63m | 7.46% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 9.30m | 6.53% |
| Wellington Management Co. LLPas of 31 Mar 2024 | 8.27m | 5.80% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 6.32m | 4.44% |
| Capital Research & Management Co. (Global Investors)as of 31 Mar 2024 | 6.05m | 4.24% |
| Temasek Holdings Pte Ltd. (Investment Management)as of 31 Mar 2024 | 5.71m | 4.00% |
| Crestline Management LPas of 31 Mar 2024 | 5.21m | 3.66% |
| Baker Bros. Advisors LPas of 31 Mar 2024 | 3.73m | 2.62% |
| Geode Capital Management LLCas of 31 Mar 2024 | 2.76m | 1.94% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
